About 35,820 results

Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Hematological Oncology; Shang Y, Jin Y et. al.

Dec 4th, 2021 - This study aimed to evaluate the existing staging systems for multiple myeloma (MM) in the real world. From January 2010 to June 2019, we retrospectively analyzed 859 newly diagnosed MM patients from two institutions. Clinical data including laboratory findings, imaging examinations and staging system were obtained by reviewing medical records. Survival distributions were estimated using the Ka...

Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
Journal of Experimental & Clinical Cancer Research : CR; Ghamlouch H, Boyle EM et. al.

Dec 4th, 2021 - Despite  improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival. The lack of a genetic basis for HR has focused attention on the role played by epigenetic changes. Aberrant expression and somatic mutations affecting genes involved in the regulation of tri-methylation of the lysine (K) 27 on histone 3...

Primary plasma cell leukemia: consensus definition by the International Myeloma Working...
https://doi.org/10.1038/s41408-021-00587-0 10.1016/0002-9343(87)90942-9 10.1001/archinte.133.5.813 10.1111/bjh.15092 10.1182/blood-2014-03-565051 10.1182/blood.V93.3.1032 10.1111/j.1365-2141.1994.tb05114.x 10.1016/S0889-8588(05)70125-8 10.1038/leu.2012.336 10.1002/cncr.31718 10.1038/leu.2008.4 10.1038/s41408-018-0153-9 10.1182/blood.V88.1.289.289 10.1038/leu.2016.205 10.1007/s00277-014-2211-0 10.3324/haematol.2016.158303 10.1038/s41408-018-0140-1 10.1182/blood-2020-141525 10.1038/leu.2012.107 10.1158/1078-0432.CCR-12-2043 10.1016/j.leukres.2018.09.007 10.1182/blood-2012-05-408682 10.1038/leu.2011.312 10.1002/ajh.23600 10.1093/annonc/mdr480 10.1038/leu.2013.241 10.1200/JCO.2015.63.1929 10.3324/haematol.2009.013334 10.1038/leu.2014.98 10.1182/blood-2005-05-1858 10.1111/bjh.13484 10.1038/s41408-018-0153-9 10.1080/10428190601016159 10.1080/1042819021000029713
Blood Cancer Journal; Fernández de Larrea C, Kyle R et. al.

Dec 4th, 2021 - Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of m...

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Dec 3rd, 2021 - To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Dec 3rd, 2021 - The primary purpose of this study is to compare the efficacy of daratumumab when combined with Velcade (bortezomib) and dexamethasone (DVd) to that of Velcade and dexamethasone (Vd), in terms of progression free survival (PFS) in Chinese participants with relapsed or refractory multiple myeloma (MM).

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Fro...

Dec 3rd, 2021 - The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation ...

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma

Dec 3rd, 2021 - Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Dec 3rd, 2021 - The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent.

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and ...

Dec 3rd, 2021 - This study will evaluate participants with newly diagnosed multiple myeloma (MM) for whom hematopoietic stem cell transplant is not planned as initial therapy. The data available from other available studies suggests that addition of daratumumab with Velcade (bortezomib), lenalidomide, and dexamethasone [VRd] is anticipated to improve the response rates and the depth of response and may lead to...

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Dec 3rd, 2021 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bispecific antibody designed to target G protein-coupled receptor family C group 5-member D (GPRC5D) and the CD3 molecule found on T lymphocytes (T cell...

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Dec 3rd, 2021 - PRIMARY OBJECTIVES: I. To assess the complete response (CR) rate with lenalidomide and sonidegib (LDE225) maintenance following an upfront single autologous stem cell transplant (SCT). SECONDARY OBJECTIVES: I. To assess the toxicity of lenalidomide and LDE225 when used as maintenance therapy in patients post autologous SCT. II. To determine the progression-free survival rate at 1 and 2 years po...

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Dec 3rd, 2021 - The study consists of 3 phases: Screening Phase (within 21 days prior to randomization), Treatment Phase (Cycle 1 Day 1 to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, withdrawal of consent, or the study ends, whichever occurs first). Treatment phase will include 2 treatments (Treatment A: participants ...

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Dec 3rd, 2021 - The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Dec 3rd, 2021 - The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for...

Dec 3rd, 2021 - The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.

Development of a new risk stratification system for patients with newly diagnosed multi...
https://doi.org/10.1038/s41408-021-00577-2 10.1182/blood-2007-10-078022 10.1038/nrc2189 10.1182/blood-2007-10-116129 10.1146/annurev-med-112017-091045 10.1200/JCO.2015.61.2267 10.1200/JCO.2005.04.242 10.7326/0003-4819-115-12-931 10.1038/leu.2009.174 10.1007/s00277-018-3316-7 10.3324/haematol.2016.145078 10.1002/ajh.24891 10.1111/bjh.14701 10.1200/JCO.2009.25.5356 10.1046/j.1365-2141.1999.01244.x 10.3324/haematol.2012.065698 10.1016/S1470-2045(14)70442-5 10.1016/S1470-2045(19)30309-2 10.1016/S1470-2045(17)30189-4 10.1182/blood-2011-06-361386 10.1182/blood-2009-03-213280 10.1158/1078-0432.CCR-15-0396 10.2967/jnumed.112.106500 10.1016/0021-9681(60)90137-5 10.1016/S1470-2045(16)30206-6 10.1038/leu.2014.230 10.1182/blood-2018-04-842880 10.1038/s41467-017-00296-y 10.3390/ijms20051248 10.1182/blood-2017-03-774422 10.1182/blood-2016-01-631200
Blood Cancer Journal; Cho HJ, Jung SH et. al.

Dec 3rd, 2021 - In multiple myeloma (MM), a high number of focal lesions (FL) detected using positron emission tomography/computed tomography (PET/CT) was found to be associated with adverse prognosis. To design a new risk stratification system that combines the Revised International Staging System (R-ISS) with FL, we analyzed the data of 380 patients with newly diagnosed MM (NDMM) who underwent 18F-fluorodeox...

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based coh...
https://doi.org/10.1038/s41408-021-00580-7 10.1016/S0140-6736(20)30183-5 10.1056/nejmoa2002032 10.1016/j.chest.2020.04.010 10.1158/2643-3230.bcd-20-0102 10.1182/blood.2020008150 10.1182/blood-2008-12-194241 10.1182/blood-2008-12-195008 10.1016/s1470-2045(14)70442-5 10.1056/nejmoa054494 10.1016/s0140-6736(10)60482-5 10.1111/j.1600-0609.1998.tb01075.x 10.3324/haematol.2011.054015 10.1182/blood-2009-11-252072 10.1182/blood-2012-07-445304 10.1016/j.bcmd.2020.102481 10.4065/84.8.685 10.1056/nejmoa2006100 10.1038/s41408-021-00480-w
Blood Cancer Journal; Rognvaldsson S, Eythorsson E et. al.

Dec 3rd, 2021 - Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individua...

Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vacc...
JAMA Oncology; Terpos E, Rajkumar SV et. al.

Dec 3rd, 2021 - Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination.|2021|Terpos E,Rajkumar SV,Leung N,|

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Dec 3rd, 2021 - This is an open-label (identity of assigned study drug will be known), multicenter, 3-part, Phase 1b dose escalation/expansion study to evaluate the safety, pharmacokinetics (study of what the body does to a drug), and antitumor activity of SC delivery of daratumumab to participant with relapsed or refractory multiple myeloma. Up to approximately 53 participants in part 1, 80 participants in pa...

A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

Dec 3rd, 2021 - This study will test the safety of TTI-621 or TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose of TTI-621 and TTI-622 that causes few or mild side effects in participants when given in combination with daratumumab hyaluronidase-fihj. Once the researchers find the highest safe dose of each st...